Novo Nordisk began a Phase 1 study of an oral obesity-drug candidate it agreed to license from Lexicon Pharmaceuticals last year. The study is investigating the safety and tolerability of the drug, ...

Designing effective lexicons is a critical component of any communications surveillance program, yet even mature teams encounter avoidable pitfalls that diminish accuracy, create operational strain, ...

THE WOODLANDS, Texas, March 05, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months and year ended December 31, 2025, and ...

THE WOODLANDS, Texas, March 03, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in an upcoming fireside chat at the 2026 ...

Lexicon Pharmaceuticals shares were 21% lower, at $1.14, after the company priced its underwritten public offering of 32 million shares at $1.30 a share. All of the shares are being offered by Lexicon ...

Lexicon Pharmaceuticals (LXRX) has priced its public offering of 32M shares of its common stock, par value $0.001, at $1.30 per share to raise $41.6M. The firm has granted the underwriters a 30-day ...

Lexicon Inc., a Little Rock-based construction management and steel fabrication company, said Thursday it has become a private, employee-owned company. Lexicon said the decision comes after a ...

Lexicon Inc., a Little Rock-based construction management and steel fabrication company, said Thursday it has become a private, employee-owned company. Subscribe to continue reading, or log in.

Shares of Lexicon Pharmaceuticals climbed after the company said the Food and Drug Administration raised no objections to moving into a Phase 3 trial of palivapadin for diabetic peripheral neuropathic ...

Our picks for the best dedicated headphone amplifiers for audiophiles includes Apos, Feliks Audio and STAX. The headphone amplifier category is in the middle of a subtle but important shift.

Lexicon Pharmaceuticals is positioned for a potential turnaround with three key drug programs and recent partnerships, despite a challenging history. LXRX's sotagliflozin faces uncertain FDA approval ...